AzurRx BioPharma Inc (AZRX) Receives a Buy from Oppenheimer


In a report released today, Leland Gershell from Oppenheimer reiterated a Buy rating on AzurRx BioPharma Inc (AZRX), with a price target of $6. The company’s shares opened today at $1.73.

Gershell noted:

“AZRX announced this morning that the first patients in its Phase 2 trial of MS1819- SD for exocrine pancreatic insufficiency due to cystic fibrosis have been dosed, and reiterated expectations that we will see top-line data in mid-2019. We are optimistic for success following positive data demonstrated in EPI within the chronic pancreatitis setting. We expect results to serve as a key catalyst for shares, which we believe significantly undervalue MS1819-SD’s prospects to become a best-in-class product in the ~$1.2B US pancreatic enzyme replacement therapy market.”

According to TipRanks.com, Gershell is a 1-star analyst with an average return of -4.1% and a 35.3% success rate. Gershell covers the Healthcare sector, focusing on stocks such as Evofem Biosciences Inc, Urogen Pharma Ltd, and Catalyst Pharma.

AzurRx BioPharma Inc has an analyst consensus of Strong Buy, with a price target consensus of $6.33, which is a 265.9% upside from current levels. In a report issued on February 14, Maxim Group also initiated coverage with a Buy rating on the stock with a $5 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $3.75 and a one-year low of $1. Currently, AzurRx BioPharma Inc has an average volume of 79.37K.

Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AZRX in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

AzurRx BioPharma, Inc. is a development stage company, which engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. It offers MS1819 and AZX1101 that are therapeutic proteins products under development. The company was founded on January 30, 2014 and is headquartered in Brooklyn, NY.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts